1. PRLog Home
  2. Business Index
  3. Pressroom Index
  4. Press Releases Home
  1. About
  2. Press Room
  3. Contact
Filter By Industry
Filter By Tag

Press Room

NAPSRx Press releases

1 - 10 of 296 Press Releases

Dec 18, 2014
The U.S. Food and Drug Administration has approved Xtoro (finafloxacin otic suspension) to treat acute otitis externa commonly referred to as swimmer's ear.

Dec 16, 2014
Pfizer has acquired the development and commercialization rights to OPKO Health’s Long-Acting Human Growth Hormone (hGH-CTP) to treat growth hormone deficiency in adults and children.

Dec 15, 2014
The U.S. Food and Drug Administration has approved Eli Lilly’s Cyramza (ramucirumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) which is the most common type of lung cancer and occurs from cancer cells forming in lung tissue.

Dec 11, 2014
A new bill has been presented by U.S. Senators Michael Bennet (D-CO) and Orrin Hatch (R-UT)  to develop a new pathway for antibiotic drug approvals called the Promise for Antibiotics and Therapeutics for Health (PATH) Act .This act is anticipated to.

Dec 10, 2014
Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) has been approved by the U.S.

Dec 08, 2014
In an attempt to accelerate their presence in the antibiotics market, Merck will acquire Cubist Pharmaceuticals for $102 per share in cash- this transaction is expected to amount to $9.5 billion.

Dec 04, 2014
Incyte Corporation has received approval for Jakafi® (ruxolitinib), the first and only FDA-approved oral medication for patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.

Dec 02, 2014
Eli Lilly will obtain an exclusive worldwide license from Zosano Pharma Corporation to commercialize their investigational therapy ZP-PTH intended to treat osteoporosis patients.

Dec 01, 2014
AstraZeneca and Eli Lilly and Company have recruited their first patient for the AMARANTH Phase II/III study to assess an oral beta secretase cleaving enzyme (BACE) inhibitor called AZD3293 which is currently being developed as a treatment option for...

Nov 26, 2014
Valeant Pharmaceuticals has received approval from the U.S Food and Drug Administration (FDA)  for ONEXTON™ Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75% for the once-daily treatment of Acne vulgaris in patients 12 and older.

RSS Feed for NAPSRx Press Releases